Cormedix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cormedix (CRMD).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

2S.Buy

8Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$16Upside to Avg. PT+110.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$15
Aug 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$14→$13
Apr 28, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
Apr 28, 2026	Citizens	Jason N. Butler	Maintained	Market Outperform	$19
Apr 28, 2026	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$13→$14
Apr 27, 2026	Needham	Serge Belanger	PT Raise	Buy	$14→$15
Apr 27, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Mar 5, 2026	Needham	Serge Belanger	PT Cut	Buy	$15→$14
Feb 11, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Jan 23, 2026	HC Wainwright & Co.	Brandon Folkes	PT Cut	Buy	$18→$13
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$22→$13
Jan 8, 2026	Needham	Serge Belanger	PT Cut	Buy	$16→$15
Jan 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Dec 18, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Nov 13, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$17→$18
Nov 12, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Nov 12, 2025	Needham	Serge Belanger	PT Cut	Buy	$20→$16
Oct 21, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$21→$22
Oct 20, 2025	D. Boral Capital	Jason Kolbert	Upgrade	Hold→Buy	$14

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $14 to $13.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

Citizens analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $19 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

Leerink Partners analyst Roanna Ruiz maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

Cormedix Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Cormedix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

People Also Watch

People Also Watch

Cormedix Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Cormedix Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRORBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PROCitizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PROLeerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

PRO
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14